Looking to the future: New agents for chronic hepatitis B

被引：12

作者：

Dienstag, JL ^{[1
]}

机构：

[1] Harvard Univ, GI Unit, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2006年 / 101卷

关键词：

D O I：

10.1111/j.1572-0241.2006.00377.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

New antiviral agents are currently being developed to treat patients with chronic hepatitis B. Both pegylated interferon alfa-2a and entecavir are now approved for the treatment of hepatitis B while telbivudine, tenofovir, emtricitabine, and pegylated interferon alfa-2b are in clinical development. Successive advances have resulted in more profound suppression of hepatitis B replication, a reduction in breakthrough resistance, and an increase in the frequency of attainment of virologic, serologic, biochemical, and histologic clinical endpoints.

引用

页码：S19 / S25

页数：7

共 29 条

[1]

Chang TT, 2004, HEPATOLOGY, V40, p193A

[2]

Chang TT, 2002, HEPATOLOGY, V36, p300A

[3]

Colonno RJ, 2004, HEPATOLOGY, V40, p661A

[4]

FEID MW, 2002, NEW ENGL J MED, V347, P975

[5] Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B [J].

Fung, SK ;

Wong, F ;

Hussain, M ;

Lok, ASF .

JOURNAL OF VIRAL HEPATITIS, 2004, 11 (05) :432-438

[6] Lamivudine-refractory hepatitis B patients can be safely switched directly to entecavir 1 mg daily therapy [J].

Gish, RG ;

Chang, TT ;

Hadziyannis, S ;

Cianciara, J ;

Rizzetto, M ;

Schiff, E ;

Pastore, G ;

Jackson, R ;

Thiry, A ;

Hindes, R .

JOURNAL OF HEPATOLOGY, 2004, 40 :127-127

[7] Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose [J].

Hadziyannis, SJ ;

Sette, H ;

Morgan, TR ;

Balan, V ;

Diago, M ;

Marcellin, P ;

Ramadori, G ;

Bodenheimer, H ;

Bernstein, D ;

Rizzetto, M ;

Zeuzem, S ;

Pockros, PJ ;

Lin, A ;

Ackrill, AM .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :346-355

[8] Results of a one-year international phase IIB trial of LDT, and LDT plus lamivudine, in patients with chronic hepatitis [J].

Han, SH ;

Leung, NWY ;

Teo, EK ;

Tong, M ;

Wong, F ;

Hann, HW ;

Poynard, T ;

Browns, NA ;

Myers, M ;

Chao, G ;

Lloyd, D ;

Lai, CL .

JOURNAL OF HEPATOLOGY, 2004, 40 :16-16

[9] Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy [J].

Honkoop, P ;

de Man, RA ;

Niesters, HGM ;

Main, J ;

Nevens, F ;

Thomas, HC ;

Fevery, J ;

Tyrrell, DL ;

Schalm, SW .

JOURNAL OF VIRAL HEPATITIS, 1998, 5 (05) :307-312

[10] Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised [J].

Janssen, HLA ;

van Zonneveld, M ;

Senturk, H ;

Zeuzem, S ;

Akarca, US ;

Cakaloglu, Y ;

Simon, C ;

So, TMJ ;

Gerken, G ;

de Man, RA ;

Niesters, HGM ;

Zondervan, P ;

Hansen, B ;

Schalm, SW .

LANCET, 2005, 365 (9454) :123-129

← 1 2 3 →